Archive for the ‘Metabolic Syndrome’ Category

Myocardial Sarcoidosis Unresponsive to Steroids: Discussion

Feb 21, 2015 Author: Walter Mcneil | Filed under: Metabolic Syndrome

This patient displayed several unusual features of sarcoidosis, namely: the large, bilateral pleural effusions, myocardial and pericardial involvement, lack of systemic “markers” for the disease process, and lack of response to steroids. It is estimated that approximately 1 percent of patients with sarcoidosis have pleural involvement. The presence of either bilateral or massive pleural effusions are usually the subjects of case reports. Sarcoidosis may affect any area of the heart—pericardium, myocardium, or endocardium. Of these, the myocardium is most frequently involved. The exact incidence of cardiac involvement, however, is difficult to ascertain. Autopsy series suggest an incidence between 20 and 30 percent, although these figures are probably quite high for all patients with sarcoidosis. Pericardial involvement, by contrast, is unusual. Only 31 cases of pericardial granulomas (usually diagnosed at necropsy) were identified by 1979. The frequency of small pericardial effusions (which may be due to disease affecting the pericardium or the epicardium) appears to be subject to the diligence of the search. Nineteen percent of 48 consecutive sarcoidosis patients in a series by Kinney et al had small pericardial effusions diagnosed by echocardiography. Thus, it is unclear how often and to what extent sarcoidosis may affect the heart. (more…)

  • Comments Off on Myocardial Sarcoidosis Unresponsive to Steroids: Discussion
  • Metabolic Syndrome

    Call-to-Action: Community Coordination to Reduce Metabolic Syndrome

    The full preventive potentials of soybeans and their derivatives can be maximized by including them in comprehensive lifestyle behavior changes. The Food and Drug Administration (October 1999) recognized the benefits of soy foods on cardiovascular diseases in its statement that daily consumptions of 25 g of soy protein combined with other lifestyle modulations (i.e., exercise) helps prevent heart disease. The American Heart Association statement on the known modifiable risk factors in heart disease suggests that physicians and healthcare provide encouragement for the incorporation of soy foods into primary preventive therapy for elevations in total and LDL. The most frequently documented soybean effect has been the decrease in the total and bad LDL cholesterols, yet soybeans are also an excellent source of dietary soluble fiber which also is known to decrease serum.


    Dose responses for varying concentrations of soybean protein were determined in 81 hypercholes-terolemic males (ages 23-74, free-living outpatients, Champaign-Urbana, IL) while being maintained on National Cholesterol Education Program Step-1 diet. (<30% energy from fat, <10% saturated fat, and <300 mg cholesterol). Pertinent baseline data included mild hypercholesterolemia (220-300 mg/dL) and the body mass index range 26.4-27.8. After a three-week lead-in period, subjects were randomly assigned to one of five experimental groups. For six weeks, each group received 50 g/day, which included isolated soy protein (ISP; Supro Plus 675 HG with 1.9 mg total isoflavone aglycone units/g protein, Protein Technologies International, St. Louis, MO) and casein (calcium caseinate, Alanate 391; New Zealand Milk Products, Wellington). The five groups received 50-, 40-, 30-, 20-, and 0 g (control) ISP and 0-, 10-, 20-, 30-, and 50 g casein, respectively. Test proteins were given through baked foods and ready-to-mix beverages, and the consumption of foods was monitored five times per week. Primary outcome measurement was change from baseline for each subject, and there were 15-18 males per group. At six weeks, non-HDL cholesterol was reduced in all groups that received ISP. The reduction in total was significant at six weeks for the groups that 20-, 30-, and 50-g ISP The 40-g ISP reduced total cholesterol 0.053 mmol/L (statistically not significant). At week six, no significant changes were found for concentrations of HDL cholesterol, tria-cylglycerol, apo A-I, or lipoprotein(a) or TC:HDL cholesterol in any group that received ISP. This trial therefore identifies a cholesterol lowering effect with doses as low as 20 g of soy protein/day in this normal-weight, mildly hypercholesterolemic male population.


    In 1991, Sanchez tried to explain these documented hypocholesterolemic effects of soy protein by suggesting that soy protein contains higher amounts of arginine and glycine than casein (animal protein) and that these amino acids induce a low postprandial glucagon ratio in both hypercholesterolemic and normocholesterolemic subjects. (Casein is known to produce a high postprandial insulin/glucagon ratio, an effect that augments atherogenesis.) Their data suggest that control of cholesterol and glucagon may be regulated by these dietary plasma amino acids. Later that year, Carroll reviewed a small number of clinical trials and numerous laboratory studies on soy and its cholesterol-lowering properties. Brief clinical observations indicated that soy protein (either alone or when added to the diets) lowered both total and LDL by approximately 20% and that hypertriglyceridemia subjects experienced a decrease in serum triglycerides tablet.


    Metabolic Syndrome: Soybean Foods and Serum Lipids

    Dec 31, 2009 Author: Walter Mcneil | Filed under: Metabolic Syndrome

    African Americans have the highest overall mortality rate and the highest out-of-hospital coronary death rates of any ethnic group in the United States, particularly at younger ages. Recent guidelines from the National Cholesterol Education Program (NCEP): Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII) indicate that lowering of LDL become the primary target in reducing coronary heart disease (CHD). Mounting evidence indicate that elevated LDL cholesterol is a major risk factor in developing CHD, and that the hypercholesterolemia tends to cluster with other cardiovascular risk factors.




    Most Popular

    • None found

    Recent Comments

    • None found